title: Beraprost sodium, an orally active prostaglandin I(2) analog, improves renal anemia in hemodialysis patients with peripheral arterial disease.
abstract: Beraprost sodium (BPS) is a stable, orally active prostaglandin I(2) (PGI(2) ) analog with antiplatelet and vasodilating properties. It has been reported that PGI(2) has pleiotropic effects that are anti-inflammatory and anti-atherogenic. In this study, we aim to determine the relationship between PGI(2) and renal anemia. We conducted a prospective randomized trial including 20 hemodialysis patients. Ten patients were assigned to be treated with 120 µg/day of BPS and the other patients were assigned to a control group. After six months, the titer of hemoglobin had significantly increased in the BPS group compared to the baseline (11.1 ± 0.3 g/dL vs. 10.3 ± 1.4 g/dL, respectively), and there was a significant difference between the BPS group and the control group. The level of ferritin was lower in the BPS group compared to the control group, but the average dose of erythropoietin did not significantly change. These findings suggest that BPS may improve renal anemia in hemodialysis patients.
authors.affiliation: Department of Nephrology and Kidney and Dialysis Center, Shonan Kamakura General Hospital, Kanagawa, Japan. hidekazu.moriya@tokushukai.jp
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Moriya
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Ishioka
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Honda
authors.forename: Machiko
authors.initials: M
authors.lastname: Oka
authors.forename: Kyoko
authors.initials: K
authors.lastname: Maesato
authors.forename: Ryota
authors.initials: R
authors.lastname: Ikee
authors.forename: Sumi
authors.initials: S
authors.lastname: Hidaka
authors.forename: Takayasu
authors.initials: T
authors.lastname: Ohtake
authors.forename: Shuzo
authors.initials: S
authors.lastname: Kobayashi
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000503:physiopathology; D011446:Prospective Studies; D006435:Renal Dialysis; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D006454:Hemoglobins; D014665:Vasodilator Agents; D004921:Erythropoietin; C048081:beraprost; D005293:Ferritins; D011464:Epoprostenol